Mitochondrial Peptide
MOTS-c is a mitochondria-derived peptide that activates the same metabolic pathways as exercise, improving fat burning, insulin sensitivity, and cellular energy output without requiring physical exertion. Its levels decline with age, making it a direct target for anyone seeking to reverse metabolic decline at the cellular level.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
15 mg
Format
Injectable
Composition
5 mg/ml per ml
MOTS-c activates AMPK (AMP-activated protein kinase), a master metabolic sensor that promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. It translocates to the nucleus and regulates gene expression involved in antioxidant defence and metabolic homeostasis. MOTS-c also inhibits the folate cycle and de novo purine synthesis, shifting cells away from biosynthetic states toward catabolism and energy production. In multiple research models, MOTS-c supplementation restored insulin sensitivity, reduced adiposity, and extended healthy lifespan.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
MOTS-c activates AMPK, the same master metabolic sensor that exercise triggers, producing measurable metabolic benefits including increased glucose uptake, fat oxidation, and mitochondrial biogenesis: even in sedentary conditions. It is one of very few compounds that genuinely replicates the biochemical effects of physical activity.
Studies of MOTS-c have reported improvements in diet-related insulin resistance, glucose tolerance, and skeletal-muscle insulin signalling. It inhibits the folate cycle, reducing a key intermediate in insulin-resistance pathways.
Longevity studies have examined MOTS-c for lifespan signalling and age-related metabolic health. Its role as a mitochondria-derived peptide that declines with age makes it a notable target in metabolic-aging research.
Under metabolic stress, MOTS-c translocates from mitochondria to the nucleus, where it regulates antioxidant gene expression and coordinates the cellular stress response: a unique dual organelle function not seen in other peptides.
By activating fat-oxidation pathways and reducing lipogenesis, MOTS-c is studied for changes in fat mass, weight gain, and visceral fat accumulation without direct appetite suppression.
As a peptide encoded in mitochondrial DNA and secreted in response to mitochondrial stress, MOTS-c serves as an autocrine and endocrine signal that restores mitochondrial function: improving ATP output and reducing oxidative damage across tissue types.
Explore selected publications and registered trials on MOTS-c, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Preclinical study
Foundational direct MOTS-c preclinical study
Publication and key finding
In mice, MOTS-c activated AMPK-linked metabolic signalling and prevented age-related and high-fat-diet-induced insulin resistance and obesity.
Cell metabolism
Evidence type
Preclinical study
Direct MOTS-c human and preclinical exercise evidence
Publication and key finding
MOTS-c increased after exercise in people and restored physical capacity and skeletal-muscle homeostasis in aged mice.
Nature communications
Evidence type
Observational study
Direct MOTS-c human observational evidence
Publication and key finding
In healthy ageing men, skeletal-muscle MOTS-c expression was associated with muscle-fibre composition, linking this mitochondrial peptide to human muscle biology.
Aging
Evidence type
Preclinical study
Direct MOTS-c muscle evidence
Publication and key finding
In mouse and muscle-cell models, MOTS-c reduced myostatin and other atrophy-related signals while supporting muscle metabolism.
American journal of physiology. Endocrinology and metabolism
Evidence type
Review
Direct MOTS-c evidence review
Publication and key finding
This review reports that circulating MOTS-c declines with age and synthesizes evidence across glucose metabolism, insulin resistance, inflammation and age-related disease models.
Frontiers in endocrinology
1 selected study from the wider trial library, in the order chosen for this product.
NCT07505745
Labbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
MOTS-c has been studied primarily in preclinical settings, where published findings have not identified significant adverse effects at research-relevant exposure. It is a mitochondria-derived peptide naturally present in human plasma, where levels decline with age. The most commonly noted observation in research settings is occasional initial fatigue as metabolic priorities shift; this typically resolves within days. Injection-site reactions are uncommon. No hepatotoxic, nephrotoxic, or cardiovascular adverse signals have been identified. Cycling is recommended to preserve receptor sensitivity.
This public COA documents one selected production batch and is updated annually. It is not the COA for our latest available batch. Every batch has its own documentation, and partners can request the latest batch COA from our team.
Other products from the same range
